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Abstract 
The regulation of phosphatidylcholine-hydrolyzing phospholipase D (PLD) by protein kinase C (PRC) in membranes of Chinese hamster lung 
fibroblasts (CCL39) was studied using conventional PKC isoforms cc, b and y isolated from rat brain and recombinant PKC isoforms. Cells were 
incubated with [Wlcholine to label endogenous phosphatidylcholine before membranes were prepared and assayed for release of [Wlcholine. PKCa 
was the most potent activator of PLD, producing a maximal effect at approximately 0.1 @ml. PKC/I also stimulated PLD but was less potent and 
less efficacious, whereas PKCy was ineffective. Stimulation required addition of a PKC activator, but the isoform specificity was the same whether 
phorbol 12-myristate 13-acetate (PMA) or Ca” was used. Recombinant Ca”-independent PKC isoforms 6, E, and [ failed to stimulate PLD, but 
recombinant PKQ?, stimulated PLD in a manner similar to the purified brain PKCB. Immunoblot analysis of the soluble fraction of CCL 39 
fibroblasts detected only the a and [ isoforms of PKC. The results suggest hat PKCa and /I are activators of PLD and that PKCa is responsible 
for the activation in these fibroblasts. 
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1. Introduction 
Activation of phosphatidylcholine-hydrolyzing phos- 
pholipase D (PLD) occurs in response to hormones and 
growth factors in many cell types [l]. Regulation of the 
enzyme may occur by mechanisms involving G-proteins 
[24], Ca2+ [4,5], unsaturated fatty acids [6], and PKC 
[7-161. Much attention has focused on the role of PKC 
in the regulation of PLD. Several studies indicate that 
down-regulation of PKC by long-term exposure to phor- 
bol ester abolishes the ability of agonists to acutely stim- 
ulate PLD [7-91. In addition, kinase inhibitors frequently 
[8-l 11, but not always [12-151, block activation of PLD 
by phorbol ester and other agonists, suggesting the in- 
volvement of both PKC-dependent and PKC-independ- 
ent mechanisms. Recently, we obtained direct evidence 
that PKC activates a PLD present in membranes from 
Chinese hamster lung (CCL39) fibroblasts [16]. Surpris- 
ingly, the stimulation apparently did not require ATP- 
dependent phosphorylation, suggesting that PKC may 
*Corresponding author. Fax: (1) (615) 322 4381. 
Abbreviations: PLD, phospholipase D; PKC, protein kinase C, PMA, 
4/?-phorbol 12-myristate 13-acetate; EGTA, [ethylenebis(oxyethyI- 
enenitrilo)]tetraacetic a id; HEPES, 4-(2-hydroxyethyl)-I-piperazine- 
ethanesulfonic acid. 
interact directly with PLD and activate it by an allosteric 
mechanism. 
PKC is a family of at least ten isoforms that are differ- 
entially regulated by Ca2+ and by phorbol esters, which 
substitute for the physiological regulator diacylglycerol 
[17,18]. Two regions of conserved sequence in the PKC 
regulatory domain which constitute phorbol ester and 
Ca2+ binding sites have been identified. The conventional 
PKC isoforms (cPKC) 01, j?,, p2 and y contain both con- 
served regions, whereas novel PKC isoforms (nPKC) 
such as 6 and E lack the Ca2’-binding region [ 17,181. 
Atypical PKC isoforms (aPKC), which include PKCC, 
lack the Ca”-binding region and contain only half of the 
phorbol ester binding region [17,18], and are insensitive 
to both activators [19]. 
Although much is known about the regulation of 
PKC, the role of the various isoforms in regulation of 
cellular processes is poorly understood. In this study, we 
have examined which isoforms are involved in regulation 
of PLD in membranes prepared from CCL39 fibroblasts. 
2. Materials and methods 
2.1. Determination of PLD activity in membranes 
Chinese hamster lung fibroblasts (CCL39) were grown, prelabelled 
with [‘%]choline, and homogenized for membrane preparation as de- 
scribed previously [16]. PLD activity was assayed by measuring the 
production of [Wlcholine. Incubations contained 20 mM HEPES pH 
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7.4, 1.1 mM EDTA, 2.1 mM EGTA, 3 mM M&l,, 5 mg/ml bovine 
serum albumin, and 0.1-0.2 mglmi membrane protein in a total volume 
of 0.1 ml and were run at 37°C for 30 min. In some cases, CaCl, was 
added and the free Ca*’ concentration was calculated using the COM- 
ICS program. Reactions were terminated with 2.5 ml methanol/chloro- 
form/water (100:50:40) and the phases were separated by addition of 
0.5 ml chloroform and 0.5 ml water. The upper phase was mixed with 
2 ml of water and centrifuged to produce an aqueous phase from which 
choline was separated from other water-soluble choline metabolites by 
ion-pair extraction using sodium tetraphenylboron 1201. A 3 ml aliquot 
of the upper phase was mixed with 1.5 ml of 10 mglml tetraphenylboron 
in 3-heptanone. After centrifugation, 1 ml of the upper (heptanone) 
phase was subjected to scintillation counting. This procedure gave 
identical results to those obtained when choline metabolites were sepa- 
rated by thin layer chromatography. 
2.2. Purification of protein kinase C isoforms 
PKCa, /I and y were purified from rat brain as described previously 
[21]. After resolution by hydroxylapatite chromatography, the identity 
of the isoforms was confirmed by immunoblot analysis using specific 
antisera. Each of the isoforms gave a single band of apparent molecular 
weight 80 kDa after SDS-PAGE and silver staining. Recombinant 
human PKC isoforms were expressed using a baculovi~s-So cell ex- 
pression system and partially purified by DEAE-Sephacel chromatog- 
raphy [22]. PKC activity was determined using a reaction mixture (0.1 
ml) containing 25 mM Tris pH 7.5, 0.2 mg/ml myelin basic protein, 5 
mM M&I,, 50 PM [Y-~‘P]ATP (5 x 10’ cpm/nmol), 1 mM dithiothre- 
itol, and 0.1 mg/ml leupeptin, and the assay conditions described previ- 
ously 1231. 
2.3. Immunoblot analysis of PKC isoforms in CCL39 cells 
Homogenates prepared from rat brain [21] and CCL39 cells [16] were 
centrifuged at 100,000 x g for 30 min. Samples of the soluble fraction 
(4 pug protein) were subjected to 10% SDS-PAGE. The gels were equili- 
brated with 48 mM Tris, 39 mM glycine, 1.3 mM SDS, and 20% 
methanol, and proteins were transferred to Immobilon-P membranes 
using a semi-dry transfer apparatus (Bio-Rad) for 1 h at 15 V. The 
membranes were blocked with 1% bovine serum albumin, 1 ml/l00 ml 
goat serum, 20 mM Tris pH 7.5, 0.9% NaCl, and 0.1% Tween 20 for 
30 min. They were then incubated with 1 @ml specific anti-PKC 
antisera and, in some cases, 1 ,&ml PKC isozyme-specific peptide in 
the same solution. Following incubation with biotinylat~ anti-rabbit 
IgG (5 fig/ml) in the same solution without albumin or serum, the blots 
were developed with a Vectastain alkaline phosphatase ABC kit. 
2.4. Materials 
[‘4C]Choline and [y3’P]ATP were from DuPont-New England Nu- 
clear. Myelin basic protein, PMA, fetal bovine serum, 3-heptanone, and 
sodium tetraphenylboron were from Sigma. Phosphatidyl~rine was 
from Avanti. Immobolin-P membranes were from Millipore. Biotinyi- 
ated anti-rabbit IgG and the Vectastain alkaline phosphatase ABC kit 
were from Vector Laboratories. Precast polyacrylamide gels were from 
Novex, Dulbecco’s modified Eagle’s Medium and polyclonal antibod- 
ies recognizing PKC a, p, y% a and 6 were from GibcofBRL. Anti-PKCG 
was from Research and Diagnostic Antibodies. Ready Organic scintil- 
lation cocktail was from Beckman. 
3. Results and discussion 
We found previously that purified rat brain PKC stim- 
ulated PLD in CCL39 membranes if PMA was also pres- 
ent [16]. Fig. 1 shows that Ca2’, another PKC activator, 
stimulates PLD, as measured by [14C]choline release, in 
the presence of PKC. Maximal stimulation occurred at 
200 nM Ca’+, a concentration lower than that required 
for stimulation of PKC activity in vitro [23]. It is possible 
that the lower Ca2* requirement for PLD activation ob- 
served here is due to the presence of endogenous PKC 
activators, such as diacylglycerol. Relatively high Ca2’ 
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Fig. 1. Ca” dependence of PLD activation by PKC. [‘4C]Choline pro- 
duction from fibroblast membranes was determined in the absence (0) 
or presence (0) of 0.3 &ml rat brain PKCa. Assay conditions were as 
described in section 2. All incubations contained 2.1 mM EGTA and 
CaCI, was added to obtain the indicated free Ca” concentration. The 
incubation with ‘0’ calcium contained only EGTA. Values are ex- 
pressed as the percentage of [‘4C]choline released in the absence of PKC 
and added CaCl,. 
concentrations timulate PKC activity in the presence of 
anionic phospholipids, but dia~ylglycerol reduces the 
concentration of Ca*’ required for activation [23]. Al- 
though some investigations have implicated Ca2’ in PLD 
regulation [4,5], our finding that Ca2’ is ineffective in the 
absence of added PKC indicates that Ca2* does not di- 
rectly activate PLD in CCL 39 membranes. In platelets, 
the increase in Ca” elicited by thrombin has been re- 
ported to stimulate PLD independently of PKC, but the 
mechanism of the Ca2’ effect was not identified [5]. In 
CCL 39 fibroblasts, however, stimulation of PLD by 
thrombin is completely blocked by protein kinase C 
down-regulation 171, suggesting that, in this cell type, the 
increase in cytosolic Ca2’ induced by this agonist [24] 
does not provoke PLD activation independently of PKC. 
The rat brain PKC that was found to be capable of 
activating PLD consisted of a mixture of the 01, p and y 
isofoirns [ 161. In order to determine which isoforms were 
active, they were resolved by hydroxylapatite chroma- 
tography [21]. Fig. 2 shows the effect of the isoforms on 
PLD activity in fibroblast membranes. PKCrr was the 
most potent and efficacious activator, having a maximal 
effect at approximately 0.1 j&ml. PKC,8 also stimulated 
PLD with a maximal effect at about 0.4 j&ml, while 
PKCy was ineffective. This pattern of stimulation held 
whether PMA (Fig. 2B) or Ca*’ (Fig. 2C) was used as 
the activator. To determine if nonclassical PKC isoforms 
could activate PLD, we made use of recombinant en- 
zymes that had been expressed in Sf9 cells and partially 
purified by DEAE-Sephacel chromatography [22]. Fig. 
3 shows that PKCG, E and 6 had no effect on PLD 
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Fig. 2. Effect of purified PKC isoforms on PLD activity. Production 
of [‘%]choline from fibroblast membranes was determined with in- 
creasing amounts of PKCcl (0). PKCj? (w), or PKCy (A) purified from 
rat brain. The incubations contained A, no activator; B, 0.5 FM PMA; 
or C, 0.2 ,uM free Ca”. Values are expressed in each case as the 
percentage of [‘4C]choline produced in the absence of PKC. 
activity, while PKC/?, activated the enzyme in a PMA- 
dependent manner. PKC/3,, which is derived from alter- 
native splicing of the same gene transcript as PKCB, [25], 
and PKCa also produced a stimulation of PLD (data not 
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shown). The S, E and [ isoforms were shown to be active 
by their ability to phospho~late myelin basic protein 
(their units of activity are given in the legend to Fig. 3). 
Immunoblot analysis of the CCL 39 soluble fraction 
was performed in order to determine which PKC 
isoforms were present in this cell type. We have shown 
previously that this soluble fraction contains a PKC re- 
sponsible for PLD activation in these fibroblasts [16]. 
Fig. 4 (lane 3) shows that only PKCct and 6 immunoreac- 
tivity could be detected. As a control to insure proper 
detection of the signal for each isoform, a sample of rat 
brain soluble fraction was included (lane 1). Due to the 
large amount of nonspecific binding, the identity of the 
PKC bands was confirmed by blocking with the isoform- 
specific peptides that were used for raising the antisera 
(lanes 2 and 4). The anti-PKCC antisera has been found 
to recognize not only this isoform, but also PKCa, which 
migrates at a slightly higher molecular weight 1261. 
The results show that PKCcr- and @ can activate PLD 
and suggest hat PKCa is the isoform responsible for the 
stimulation in CCL 39 cells. As activation of PLD by 
phorbol esters occurs in nearly all cell types [l], it would 
be expected that the PKC isoforms involved be ubiqui- 
tously expressed. Indeed, Westal et al. [27] found PKCa! 
i~unoreacti~ty in all eight rat tissues they examined, 
while PKC/3, and& were present in nearly all tissues. In 
addition, either PKCa or ,8 is apparently expressed in all 
cultured cell lines [28]. 
The finding that PKCP activated PLD is supported by 
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Fig. 3. Lack of PLD activation by recombinant Ca*‘-independent PKC 
isoforms and stimulation by recombinant PKCB,. [W]Choline release 
from fibroblasts membranes was determined without added PKC or 
with 2.2 units/ml PKCG, I .7 units/ml PKCE, 0.5 units/ml PKa, or 0.7 
units/ml PKCB,. Incubations were run in the absence or presence of 0.5 
PM PMA. Values are expressed as the percentage of [‘YJ]choline re- 
ieased in the absence of PKC or PMA. The mean + S.D. of samples 
run in triplicate is shown. 
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Fig. 4. Immunoblot analysis of PKC isoforms in CCL 39 soluble fraction. Samples (4 jig protein) of rat brain (lanes 1 and 2) or fibrobiast (lanes 
3 and 4) soluble fractions were subjected to SDS-PAGE and i~unoblotted as described in section 2. To demonstrate specific binding, blots were 
incubated with the appropriate antisera in the absence (lanes 1 and 3) or presence (lanes 2 and 4) of PKC isoform-specific peptide. Arrows indicate 
the position of the various PKC bands. The position of molecular weight markers is given in kDa. 
the demonstration that PKCbI overexpression in rat fi- 
broblasts enhances PMA-stimulated PLD activity [29]. 
However, recent studies with Swiss 3T3 fibroblasts over- 
expressing PKCa. suggest that this isoform is not in- 
volved in the acute stimulation of PLD by PMA, but 
rather that it plays a role in expression of the PLD en- 
zyme [30]. Also in apparent contradiction to the present 
results is the recent report suggesting that PKCE is an 
activator of PLD in mesangiat cells 1311. The reasons for 
the differences between those studies and our results is 
unknown but may involve the presence of different PLD 
isoforms in the various cell types. The existence of PLD 
isoforms has been suggested based on the observation 
that different preparations of the enzyme differ in sub- 
strate, detergent, and cation requirements [32]. It is also 
likely that PLD activation by PKC takes place by both 
phosphorylation-dependent and -independent mecha- 
nisms. We have obtained evidence that, in CCL 39 mem- 
branes, the stimulation of PLD occurs independently of 
protein phosphorylation [16], raising the possibility that 
PKC may bind directly to PLD and activate it by an 
allosteric mechanism. However, experiments using other 
cell types suggest a dependence on ATP 18-l 1,331. Only 
after PLD has been isolated can the mechanism(s) of 
activation be tested directiy. If, in fact, different PLD 
isoforms exist, their isolation should allow examination 
of the possibility that they are differentially regulated by 
PKC isoforms. 
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